The Infliximab Total Anti-Drug Antibody ELISA is intended for the semi-quantitative determination of human antibodies against TNFα blocker infliximab (e.g. Remicade®) in the presence of infliximab in human serum and EDTA plasma. For Research Use Only in the United States. Health Canada Licensed.
Health Canada Licensed, Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available in North America Only
Sizes
96 Wells
Sample Types
EDTA Plasma, Serum
Inc Time Hour
1
Inc Time Minute
50
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
100
Detection
Colorimetric
This ELISA serves for the determination of antibodies against the TNF-α-blocker infliximab (e.g., Remicade®). During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody to acquire free ADA. By adding the peroxidase-labelled conjugate (PODlabelled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced, and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product. The enzymatic reaction is stopped by addition of an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
The ALPCO Glucagon ELISA is for the quantitative determination of glucagon in human EDTA plasma. This assay was developed for ease-of-use and demonstrates superior sensitivity while eliminating cross-reactivity issues present in other commercially-available assays.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
Join our speaker from Department of Pathology , University of Utah School of Medicine, Dr. Heather Nelson, to discuss how to validate and launch a FDA-approved assay.
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.
